Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha

Chinese Medical Journal

Volumn 123, Issue 7, 2010, Pages 936-941

  Wang, You Min ^a   Wang, Wen Ping ^a   Wang, Li Ping ^a   Lü, Qi Huan ^a   Zhou, Xiao Hui ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Calorie control; Diet induced obese rats; Pioglitazone; Vaspin

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISCERAL ADIPOSE TISSUE DERIVED SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; HYPERINSULINEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS FAT; THERAPY EFFECT;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CELL DIFFERENTIATION; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; INSULIN; MALE; MICE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950882568     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.07.031     Document Type: Article

References (21)

1. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-325.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
3. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
4. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005; 102: 10610-10615.
5. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008; 17: 327-333.
6. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008; 36: 625-629.
7. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
8. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
9. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276: 16683-16689.
10. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006: 116: 3015-3025.
11. Björntorp P. Metabolic implication of body fat distribution. Diabetes Care 1991; 14: 1132-1143.
12. Frayn KN. Visceral fat and insulin resistance-causative or correlative? Br J Nutr 2000; 83 (Suppl 1): S71-S77.
13. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
14. Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009; 84: 325-328.
15. Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65-70.
16. Sharma AM, Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
17. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005; 5: 349-363.
18. Laplante M, Festuccia WT, Soucy G, Gélinas Y, Lalonde J, Berger JP, et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006; 55: 2771-2778.
19. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008; 93: 3165-3172.
20. Ishizuka K, Usui I, Kanatani Y, Bukhari A, He J, Fujisaka S, et al. Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology 2007; 148: 2994-3003.
21. Cheng YL, Li L, Yang GY, Shi SC, Chen Y, Zhu W, et al. Effects of tumor necrosis factor-alpha induced insulin resistance on adipose triglyceride lipase in mice. Natl Med J China (Chin) 2008; 88: 2417-2421.